Effective management of patients with dyslipidemia

American Journal of Managed Care

Volumn 9, Issue 2 SUPPL., 2003, Pages

  Lipsy, Robert J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE SALT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ARTHRALGIA; BACKACHE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ERUCTATION; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE PLANNING; HEALTH EDUCATION; HEALTH PROGRAM; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; ISCHEMIC HEART DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; MANAGED CARE; META ANALYSIS; METEORISM; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK ASSESSMENT; SCREENING; SECONDARY PREVENTION; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; UNITED STATES; UNPLEASANT DREAM; UPPER RESPIRATORY TRACT INFECTION; VIVID DREAM;

EID: 0037291197     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. National Committee on Quality Assurance. Cholesterol Management and Screening Control. Available at: http://www.ncqa.org/somc2001/CHOLESTEROL/SOMC_2001_CHM.html. Accessed November 10, 2002.
3. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association; 2001.
4. Castelli WP. Epidemiology of coronary heart disease: The Framingham Study. Am J Med. 1984;76:4-12.
5. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation. 1998;97:946-952.
6. American Heart Association. Biostatistical fact sheet - Risk factors; High blood cholesterol and other lipids. Available at: http://www.americanheart.org/downloadable/heart1017696825613chollip.pdf. Accessed November 7, 2002.
7. Shepard J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
8. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
11. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
13. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
14. Pedersen TR, Olsson AG, Færgeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
15. Brown WV. Cholesterol lowering in atherosclerosis. Am J Cardiol. 2000:24;86(4B):29H-32H.
16. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus revascularization treatment investigators. N Engl J Med. 1999;341:70-76.
17. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA. 2001;285:1711-1718.
18. Davidson M, Ma P, Stein E, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268-275.
19. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
20. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995;29:743-759.
21. Cressman MD, Hooquewerf BJ, Moodie DS, Loin JW, Weinstein CE. HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia. Clev Clin J Med. 1988;55:93-100.
22. Pasternak RC, Smith B, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024-1028.
23. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
24. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors? Clin Ther. 1994;16:366-385.
25. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:14-17.
26. Simonson SG, Martin PD, Mitchell PD, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects [abstract]. Clin Pharmacol Ther. 2001;69:P86. Abstract PIII-88.
27. Martin PD, Dane AL, Schneck DW, et al. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol. 2000;40:1056. Abstract 48.
28. Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann Pharmacother. 2002;36:93-101.
29. Olsson A, Southworth H, Wilpshaar JW. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus atorvastatin. Eur Heart J. 2001;22(suppl):253. Abstract 1410.
30. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovas Risk. 2001;8:383-390.
31. Brown WV, Chitra RR, Zedler BK, Bays HE, Hassman H. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin [abstract]. Eur Heart J. 2001;22(suppl):270.
32. Morgan JM, Cressman MD, Hutchinson HG, Capuzzi DM. Beneficial effects of combination therapy with rosuvastatin and extended-release niacin in patients with mixed dyslipidemia. [abstract]. Presented at: International Symposium on Drugs Affecting Lipid Metabolism (DALM); September 9-13, 2001; New York, NY.
33. Ballantyne C, Miller E, Chitra R. Rosuvastatin alone produces similar lipid benefits compared with rosuvastatin plus cholestyramine in patients with primary hypercholesterolemia. Paper presented at: International Symposium on Drugs Affecting Lipid Metabolism (DALM); September 9-13, 2001; New York, NY.
34. Durrington P, Hamann A, Tuomilehto J, Smith K, Kallend D. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetologia. 2001;44(suppl 1):A165. Abstract 631.
35. Hunninghake DB, Chitra RR, Simonson SG, Schneck DW. Effects of rosuvastatin on serum lipids and lipid subfractions in patients with hypertriglyceridemia [abstract]. Presented at: International Symposium on Drugs Affecting Lipid Metabolism (DALM); September 9-13, 2001; New York, NY.
36. Stein E, Strutt KL, Miller E, Southworth H, for the HEFH Study Group. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia [abstract]. J Am Coll Cardiol. 2001;37(suppl A):292A. Abstract 1261-176.
37. Knopp RH, Ballantyne CM, McPherson R, et al. Comparing rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia [abstract]. Eur Heart J. 2002;4(suppl):19.
38. Rosuvastatin Outcomes Program. Presented at: Annual Congress of the European Society of Cardiology Meeting (ESC); August 31-September 4, 2002, Berlin, Germany.
39. Grundy SM, Vega GL, McGovern ME, et al. Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type-2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568-1576.
40. Advicor [package insert]. Miami, FL: Kos Pharmaceuticals, Inc; 2002. Available at: http://www.advicor.com/hcp.html. Accessed November 7, 2002.
41. Van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235 and its glucuronide, SCH60663. Br J Pharmacol. 2000;129:1748-1754.
42. Knopp RH, Gitter H, Truitt T, et al. Ezetimibe reduces low-density lipoprotein cholesterol: Results of a phase III randomized, double blind, placebo-controlled trial [abstract]. Atherosclerosis. 2001;2:38.
43. Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin [abstract]. Atherosclerosis. 2000;151:135.
44. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
45. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment eligible United States adults. Am J Cardiol. 1998;82:61-65.
46. Qureshi AI, Suri MFK, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population. Report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001;161:1621-1628.
47. Lai LL, Poblet M, Bello C. Are patients with hyperlipidemia being treated? Investigation of cholesterol treatment practices in an HMO primary care setting. South Med J. 2000;93:283-286.
48. Williams ML, Morris MT II, Ahmad U, Yousseff M, Li W, Ertel N. Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center. Ethnic Dis. 2002;12:S58-S62.
49. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.
50. Caro J, Klittich W, McGuire A, et al. The West of Scotland Coronary Prevention Study: Economic benefit analysis of primary prevention with pravastatin. BMJ. 1997;315:1577-1582.
51. B-blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714.
52. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med. 1993;153:1863-1868.
53. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med. 2000;9:1169-1175.
54. Simons LA, Lewis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164:208-211.
55. Sung JCY, Nichol MB, Venturini F, Bailey KL, McCombs JS, Cody M. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998;4:1421-1430.
56. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1999;333:1125-1131.
57. Andrade SE, Saperia GM, Berger ML, Platt R. Effectiveness of antihyperlipidemic drug management in clinical practice. Clin Ther. 1999;21:1973-1987.
58. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA. 1998;279:1458-1462.
59. Robinson JG, Conroy G, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol < 100 mg/dL. Am J Cardiol. 2000;85:305-308.
60. Brown AS, Cofer LA. Lipid management in a private cardiology practice (the Midwest heart experience). Am J Cardiol. 2000;85(suppl):18A-22A.
61. Becker DM, Raqueno JV, Yook RM, et al. Nurse-mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. Arch Intern Med. 1998;158:1533-1539.
62. The Kaiser Foundation Health Plan and the Permanente Medical Group of Ohio. Improvement of cardiac outcomes in Kaiser Permanente of Ohio. Permanente J [serial online]. Spring 2000;4(2). Available at: http://www.kaiserpermanente.org /medicine/permjournal/spring00pj/cad.html. Accessed September 3, 2002.
63. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 2002;162:1149-1155.
64. Faulkner MA, Wadibia EC, Lucus BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization, a randomized controlled clinical trial. Pharmacotherapy. 2000;20:410-416.
65. O'Donnell DC, Chen WT, Piziak VK. Goal attainment and maintenance of serum cholesterol level in a pharmacist-coordinated lipid clinic. Am J Health Syst Pharm. 2001;58:325-330.